Intensified neoadjuvant radio-chemotherapy for locally advanced rectal cancer: mono-istitutional experience and long-term results

Authors

  • A. Basile UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
  • A. Di Cataldo UOC Chirurgia Digerente Colorettale, AOU Policlinico-VE di Catania
  • A. Tocco UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
  • C. Spatola UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
  • G. Acquaviva UOC Radioterapia, AOE Cannizzaro, via Messina 829, 95125 Catania
  • G. Privitera UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
  • L. Raffaele UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
  • P. Milone UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
  • P.V. Foti UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
  • R. Bevilacqua UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
  • R. Milazzotto UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
  • V. Salamone UOC Radiodiagnostica e Radioterapia oncologica, AOU Policlinico-VE, via S.Sofia 78, 95125 Catania, Italy
Abstract:

Background: Purpose: The purpose of our study is to demonstrate that intensified neoadjuvant chemo-radiotherapy (CRT) treatment in locally advanced rectal cancer (LARC), aimed at further enhancing the complete pathological response and local disease control, is feasible and well tolerated.  Materials and Methods: From January 2011 to December 2015, 62 patients (women 21, men 41, mean age 61,5, range 36-84) with LARC (cT2-3 cN0-2) were enrolled in our institution. All patients performed an intensified neo-adjuvant CRT treatment according to the following scheme: FOLFOX4 induction chemotherapy for 3 cycles, followed by a concomitant radio-chemotherapy, with concomitant boost pelvic radiotherapy to a total dose to the primary of 54 Gy and daily continuous infusion of 5-Fluorouracil. After 6-8 weeks pts were re-evaluated by means of colonoscopy, body TC and pelvic MRI. Results: Intensified CRT compliance was 90%. Grade I-II proctitis according to CTCAE v4.0 was 43%, grade III diarrhea was 10%, grade I-II genito-urinary toxicity was 29%. Eleven patients (19%) had a complete pathological response (pCR), 37 patients had a partial response. Sixty patients received surgery, two refused it: sphincter-saving procedure was performed in 85% of patients, Miles’ surgery in 15% of them. Fifty-nine patients are alive, after a median follow-up time of 43 months. Six patients experienced a distant metastatic disease, and two patients a local relapse. Conclusion: This study has shown that the intensification of preoperative systemic therapy, together with intensification of radiotherapy, was feasible, well tolerated and has obtained high rates of local disease control (96,5%), with 19% of pCR rate.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Neoadjuvant chemotherapy for locally advanced breast cancer.

Preoperative systemic therapy is the standard of care in locally advanced breast cancer. In this setting, the intent of preoperative systemic therapy is to expand surgical options and to improve survival. Locally advanced and inflammatory breast cancer have different biological features, but they share the use of preoperative (primary, neoadjuvant) systemic therapy as the initial treatment of c...

full text

Neoadjuvant chemotherapy for locally advanced cervical cancer

Neoadjuvant chemotherapy followed by surgery (NCS) has not been fully evaluated clinically. Currently, the main regimen of neoadjuvant chemotherapy (NAC) used in NCS includes cisplatin. The antitumor effects of NAC reduce lymph node metastasis and the tumor diameter in patients prior to surgery, and this can reduce the number of high risk patients who require postoperative radiation therapy. Ma...

full text

Response to neoadjuvant chemotherapy in locally advanced gastric and gastroesophageal cancer: Phase II clinical trial

Background: Gastric cancer is an important health problem across the world. Chemotherapy in combination with local treatment is standard treatment for locally advanced gastroesophageal cancers. The purpose of this investigation was evaluation of response and tolerability to neoadjuvant EOX regimen in locoregionally advanced gastric cancer. Materials and Methods: patients with locoregionally adv...

full text

Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer

BACKGROUND This study evaluated the effectiveness and safety of preoperative chemoradiotherapy with capecitabine in patients with locally advanced resectable rectal cancer. This report summarizes the results of the phase II study together with long-term (5-year) follow-up. METHODS Between June 2004 and January 2005, 57 patients with operable, clinical stage II-III adenocarcinoma of the rectum...

full text

A Review of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer

Neoadjuvant chemoradiotherapy has become the standard treatment for locally advanced rectal cancer. Neoadjuvant chemoradiotherapy not only can reduce tumor size and recurrence, but also increase the tumor resection rate and anus retention rate with very slight side effect. Comparing with preoperative chemotherapy, preoperative chemoradiotherapy can further reduce the local recurrence rate and d...

full text

Postmastectomy Radiotherapy for Locally Advanced Breast Cancer Receiving Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy (NAC) is widely used in locally advanced breast cancer (BC) treatment. The role of postmastectomy radiotherapy (PMRT) after NAC is strongly debated. The aim of our analysis was to identify major prognostic factors in a single-center series, with emphasis on PMRT. From 1997 to 2011, 170 patients were treated with NAC and mastectomy at our center; 98 cases (57.6%) underwe...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 17  issue 2

pages  265- 273

publication date 2019-04

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023